Arabic Arabic English English French French German German
dark

Public Meeting on Patient Focused Drug Development for Psoriasis Part 2

On March 17, 2016, FDA hosted a public meeting on Patient-Focused Drug Development for Psoriasis. FDA was interested in obtaining patient perspectives on the impact of psoriasis on daily life and patient views on treatment approaches. FDA was interested in patient’s perspectives for the types of psoriasis with primarily skin symptoms (such as plaque psoriasis, nail psoriasis, guttate psoriasis, etc.). For more information, visit https://go.usa.gov/xHDac.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Philips and Ibex Medical Analytics team to accelerate adoption of AI-powered digital pathology

Next Post

Heart Patch Helps Grow New Vessels Post Myocardial Infarct

Related Posts
Total
0
Share